GSK agrees to $10.6 billion Nuvalent acquisition amid biotech deal surge
The confirmed price of $10.6 billion exceeds initial estimates of more than $9 billion, as the sector responds to looming patent expirations and strong public markets.
UK pharmaceutical company GSK has agreed to acquire US drugmaker Nuvalent for $10.6 billion, a transaction that underscores the intensifying competition among major drugmakers to expand their portfolios. The confirmed valuation represents an increase from earlier reports suggesting the deal would be valued at more than $9 billion.
The acquisition is part of a broader surge in biotech dealmaking, a trend driven by three primary factors: impending patent expirations, buoyant public markets, and the industry’s urgent need to strengthen drug pipelines. This strategic consolidation allows established players to secure innovative assets before key patents expire, protecting future revenue streams.
The announcement coincides with a positive shift in US equity markets. On the day of the news, the Dow Jones Industrial Average gained 0.8%, the S&P 500 rose 0.3%, and the Nasdaq Composite climbed 0.2%. Market sentiment was further bolstered by Nvidia shares, which surged more than 2% following the US approval of H200 chip sales to Chinese firms.
This financial activity occurs against the backdrop of a summit between US President Donald Trump and Chinese President Xi Jinping in Beijing, which began on Thursday. The two-day meeting focuses on trade, artificial intelligence, and tensions regarding Iran, adding a layer of geopolitical context to the day’s market movements.
While the deal price has been settled, the source material does not specify the timeline for regulatory approval or the final closure of the transaction. Nor does it detail the specific composition of GSK’s pipeline gains from the acquisition. The move highlights the sector's reliance on capital markets to fund growth in a competitive landscape.
